Vascular Inflammation and Cholesterol Lowering Therapy

Phase 4

Withdrawn

• Conditions: Lipid Lowering, Vascular Inflammation
• Interventions: Drug: Evolocumab or Alirocumab

• Registration Number: NCT02941016
• Lead Sponsor: Rigshospitalet, Denmark

Brief Summary

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2016-10-18
• Study First Submitted QC: 2016-10-20
• Study First Posted: 2016-10-21
• Status Verified: 2020-10
• Primary Completion: 2020-10
• Study Completion: 2020-10-01
• Last Update Submitted: 2020-10-12
• Last Update Posted: 2020-10-14

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• treatment with PCSK-9 inhibitors

Exclusion Criteria

• Infection Pregnancy Severe claustrophobia Weight >140 kg

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lipid lowering	Evolocumab or Alirocumab	-

Primary Outcome Measures

Name	Time	Method
Change in vascular inflammation	12 weeks	Change in standard uptake value (SUV) of flourdeoxyglucose (FDG) before and after initiation of lipid lowering therapy

Trial Locations

Locations (1)

Rigshospitalet; 🇩🇰 Copenhagen, Denmark